Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms of drug resistance and guided the design of tight-binding inhibitors for resistant variants. The plethora of structures reveals distinct molecular mechanisms associated with resistance: mutations that alter the protease interactions with inhibitors or substrates; mutations that alter dimer stability; and distal mutations that transmit changes to the active site. These insights will inform the continuing design of novel antiviral inhibitors targeting resistant strains of HIV
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insig...
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodefic...
The evolution of drug resistance in HIV has been a major obstacle in combating the AIDS epidemic, an...
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-...
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-...
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
Drug resistance is a major obstacle in modern medicine. However, resistance is rarely considered in ...
AbstractDrug resistance is a major obstacle in modern medicine. However, resistance is rarely consid...
AbstractDrug resistance is a major obstacle in modern medicine. However, resistance is rarely consid...
Human immunodeficiency virus type 1 (HIV-1) protease (PR) plays an essential role in the life cycle ...
SummaryThis report examines structural changes in a highly mutated, clinical multidrug-resistant HIV...
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
Amino acid changes within HIV protease or its substrate that decrease the susceptibility to protease...
Amino acid changes within HIV protease or its substrate that decrease the susceptibility to protease...
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insig...
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodefic...
The evolution of drug resistance in HIV has been a major obstacle in combating the AIDS epidemic, an...
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-...
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-...
HIV affects the lives of about 37 million patients worldwideincluding around one million Americans. ...
Drug resistance is a major obstacle in modern medicine. However, resistance is rarely considered in ...
AbstractDrug resistance is a major obstacle in modern medicine. However, resistance is rarely consid...
AbstractDrug resistance is a major obstacle in modern medicine. However, resistance is rarely consid...
Human immunodeficiency virus type 1 (HIV-1) protease (PR) plays an essential role in the life cycle ...
SummaryThis report examines structural changes in a highly mutated, clinical multidrug-resistant HIV...
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
Human immunodeficiency virus type 1 protease (HIV-1 PR) is an essential enzyme in the HIV-1 life cy...
Amino acid changes within HIV protease or its substrate that decrease the susceptibility to protease...
Amino acid changes within HIV protease or its substrate that decrease the susceptibility to protease...
Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insig...
Under the selective pressure of protease inhibitor therapy, patients infected with human immunodefic...
The evolution of drug resistance in HIV has been a major obstacle in combating the AIDS epidemic, an...